![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.379, 2002-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Primary prophylaxis cost effective in severe haemophilia?
Inpharma, Vol. 1, Iss. 1354, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Inpharma, Vol. 1, Iss. 1292, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New strategies to defeat haemophilia?
Inpharma, Vol. 1, Iss. 1405, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dalteparin cost effective for VTE prophylaxis in the US?
Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dalteparin cost effective for VTE prophylaxis in the US?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 488, 2005-01 ,pp. :